To Amend The Prescription Drug Monitoring Program Advisory Committee; And To Amend The Confidentiality Of And The Providing Of Information By The Prescription Drug Monitoring Program.
Relating to the regulation of prescriptions for controlled substances, including certain procedures applicable to electronic prescriptions for Schedule II controlled substances.